Meeting
2014 ASCO Annual Meeting
NCI experience using yeast-brachyury vaccine (GI-6301) in patients (pts) with advanced chordoma.
Authors
Christopher Ryan Heery
Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD
Christopher Ryan Heery , Harpreet Singh , Jennifer L. Marte , Ravi Amrit Madan , Geraldine Helen O'Sullivan Coyne , Benedetto Farsaci , Timothy C. Rodell , Claudia Palena , Jeffrey Schlom , James L. Gulley
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Immunotherapy and Biologic Therapy
Clinical Trial Registration Number
NCT01519817
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 3081)
DOI
10.1200/jco.2014.32.15_suppl.3081
Abstract #
3081
Poster Bd #
148
Abstract Disclosures
Similar Posters
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Preliminary biomarker and pharmacodynamic data from a phase I study of single-agent bispecific antibody T-cell engager GBR 1302 in subjects with HER2‑positive cancers.
First Author: Martin Wermke
Poster
2023 ASCO Annual Meeting
A phase Ib study of endogenous T cell therapy using SLC45A2-specific CD8 T cells for patients with metastatic uveal melanoma.
First Author: Suzanne Phillips
First Author: Patrick Roth
Poster
2015 ASCO Annual Meeting
Phosphatidylserine targeting antibody in combination with anti-PD-1 antibody treatment activates infiltrating T lymphocytes of the spleen and tumor microenvironment in pre-clinical models of melanoma and breast cancer.
First Author: Xianming Huang